CoChat

Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: The clinical effectiveness of parenterally-administered glucagon-like peptide-1 (GLP-1) mimetics to improve glucose control in patients suffering from type 2 diabetes strongly supports discovery pursuits aimed at identifying and developing orally active, small molecule GLP-1 receptor agonists. The purpose of these studies was to identify and characterize novel nonpeptide agonists of the GLP-1 receptor. RESEARCH DESIGN AND METHODS: Screening using cells expressing the GLP-1 receptor and insulin secretion assays with rodent and human islets were used to identify novel molecules. The intravenous glucose tolerance test (IVGTT) and hyperglycemic clamp characterized the insulinotropic effects of compounds in vivo. RESULTS: Novel low molecular weight pyrimidine-based compounds that activate the GLP-1 receptor and stimulate glucose-dependent insulin secretion are described. These molecules induce GLP-1 receptor-mediated cAMP signaling in HEK293 cells expressing the GLP-1 receptor and increase insulin secretion from rodent islets in a dose-dependent manner. The compounds activate GLP-1 receptor signaling, both alone or in an additive fashion when combined with the endogenous GLP-1 peptide; however, these agonists do not compete with radiolabeled GLP-1 in receptor-binding assays. In vivo studies using the IVGTT and the hyperglycemic clamp in Sprague Dawley rats demonstrate increased insulin secretion in compound-treated animals. Further, perifusion assays with human islets isolated from a donor with type 2 diabetes show near-normalization of insulin secretion upon compound treatment. CONCLUSIONS: These studies characterize the insulinotropic effects of an early-stage, small molecule GLP-1 receptor agonist and provide compelling evidence to support pharmaceutical optimization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db10-0689

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. The chemical structures of two pyrimidine-based GLP-1 receptor agonists, compound A (A) and compound B (B) are depicted.
FIG. 1. The chemical structures of two pyrimidine-based GLP-1 receptor agonists, compound A (A) and compound B (B) are depicted.CC BY-NC-ND · PubMed Central
FIG. 2. Low molecular weight GLP-1 receptor agonists activate GLP-1 receptor signaling. A: Compound A and compound B induced GLP-1 receptor-mediated signaling in HEK293 cells coexpressing the human GLP-1 receptor and a 3x-cAMP response element-luciferase reporter, but were not active in cells lacking the GLP-1 receptor. In the human GLP-1 receptor HEK293 cells, the EC50 values for compounds A and B were 1.6 μmol/l and 0.66 μmol/l, respectively; data are presented as percentages of stimulation of a maximum concentration of human GLP-1. B: The competitive GLP-1 receptor peptide antagonist exendin (9-39) blunted GLP-1 peptide activity but did not reduce compound B-induced signaling. C: Compound B was active in HEK293 cells expressing a modified form of the GLP-1 receptor lacking the NH2-terminal ECD (Δ–ECD-GLP-1 receptor); the native GLP-1 peptide had no effect in cells expressing the Δ–ECD-GLP-1 receptor. D: Compound B was not active in HEK293 cells expressing the glucagon-like peptide-2 receptor (GLP-2R), glucose-dependent insulinotropic polypeptide receptor (GIP-R), glucagon receptor (GCG-R), or parathyroid hormone receptor (PTH-R).
FIG. 2. Low molecular weight GLP-1 receptor agonists activate GLP-1 receptor signaling. A: Compound A and compound B induced GLP-1 receptor-mediated signaling in HEK293 cells coexpressing the human GLP-1 receptor and a 3x-cAMP response element-luciferase reporter, but were not active in cells lacking the GLP-1 receptor. In the human GLP-1 receptor HEK293 cells, the EC50 values for compounds A and B were 1.6 μmol/l and 0.66 μmol/l, respectively; data are presented as percentages of stimulation of a maximum concentration of human GLP-1. B: The competitive GLP-1 receptor peptide antagonist exendin (9-39) blunted GLP-1 peptide activity but did not reduce compound B-induced signaling. C: Compound B was active in HEK293 cells expressing a modified form of the GLP-1 receptor lacking the NH2-terminal ECD (Δ–ECD-GLP-1 receptor); the native GLP-1 peptide had no effect in cells expressing the Δ–ECD-GLP-1 receptor. D: Compound B was not active in HEK293 cells expressing the glucagon-like peptide-2 receptor (GLP-2R), glucose-dependent insulinotropic polypeptide receptor (GIP-R), glucagon receptor (GCG-R), or parathyroid hormone receptor (PTH-R).CC BY-NC-ND · PubMed Central
FIG. 3. Compound B increases glucose-dependent insulin secretion from SD rat islets. A: Insulin concentrations from static cultures of SD rat islets incubated in media containing low glucose (2.8 mmol/l) and either GLP-1 (100 nmol/l), compound B (3 μmol/l), or the sulfonylurea glibenclamide (5 μmol/l). B: Insulin concentrations from static cultures of SD rat islets incubated in media containing high glucose (11.2 mmol/l) and either GLP-1 (100 nmol/l) or various concentrations of compound B (0.3–10 μmol/l). All islet treatments were performed for 90 min. Results are expressed as mean ± SEM, *P < 0.05.
FIG. 3. Compound B increases glucose-dependent insulin secretion from SD rat islets. A: Insulin concentrations from static cultures of SD rat islets incubated in media containing low glucose (2.8 mmol/l) and either GLP-1 (100 nmol/l), compound B (3 μmol/l), or the sulfonylurea glibenclamide (5 μmol/l). B: Insulin concentrations from static cultures of SD rat islets incubated in media containing high glucose (11.2 mmol/l) and either GLP-1 (100 nmol/l) or various concentrations of compound B (0.3–10 μmol/l). All islet treatments were performed for 90 min. Results are expressed as mean ± SEM, *P < 0.05.CC BY-NC-ND · PubMed Central
FIG. 4. GLP-1 and compound B increase GLP-1 receptor signaling in an additive manner. A: Combination treatment of the GLP-1 peptide and compound B increases the intracellular concentration of cAMP in HEK293 cells expressing the human GLP-1 receptor. Treatment times for the cAMP assays were 20 min. B: Insulin concentrations from static cultures of SD rat islets incubated in media containing high glucose (11.2 mmol/l) and compound B plus increasing concentrations of GLP-1. Islet treatments were performed for 90 min. Results are expressed as mean ± SEM, *P < 0.05.
FIG. 4. GLP-1 and compound B increase GLP-1 receptor signaling in an additive manner. A: Combination treatment of the GLP-1 peptide and compound B increases the intracellular concentration of cAMP in HEK293 cells expressing the human GLP-1 receptor. Treatment times for the cAMP assays were 20 min. B: Insulin concentrations from static cultures of SD rat islets incubated in media containing high glucose (11.2 mmol/l) and compound B plus increasing concentrations of GLP-1. Islet treatments were performed for 90 min. Results are expressed as mean ± SEM, *P < 0.05.CC BY-NC-ND · PubMed Central
FIG. 5. Compound B increases plasma insulin levels in the SD rat IVGTT model. Time course of plasma (A) glucose and (B) insulin concentrations in fasted, anesthetized animals treated with either vehicle (■), GLP-1 (×) (10 μg/kg), or compound B (○) (dosed at 10 mg/kg) immediately before intravenous administration of a glucose bolus (0.5 g/kg). Results are expressed as mean ± SEM. C: AUC of the insulin excursion curves for vehicle versus the GLP-1 or compound B treatment groups, *P < 0.05.
FIG. 5. Compound B increases plasma insulin levels in the SD rat IVGTT model. Time course of plasma (A) glucose and (B) insulin concentrations in fasted, anesthetized animals treated with either vehicle (■), GLP-1 (×) (10 μg/kg), or compound B (○) (dosed at 10 mg/kg) immediately before intravenous administration of a glucose bolus (0.5 g/kg). Results are expressed as mean ± SEM. C: AUC of the insulin excursion curves for vehicle versus the GLP-1 or compound B treatment groups, *P < 0.05.CC BY-NC-ND · PubMed Central
FIG. 6. Compound B increases plasma insulin levels in the SD rat hyperglycemic clamp model. A: Intravenous dosing with vehicle (■) or 10 mg/kg compound B (○) occurred immediately before intravenous infusion of glucose. Glucose levels measured from venous blood every 5 min are shown. Results are expressed as mean ± SEM. B: Blood glucose concentrations of ∼250 mg/dl were maintained throughout the experiment by varying the glucose infusion rates. C: Time course of plasma insulin concentrations in fasted animals treated with either vehicle (■) or compound B (○). Results are expressed as mean ± SEM. D: AUC20–60 min of the insulin secretion for vehicle (filled bar) versus compound B-treated (open bar) animals, *P < 0.05.
FIG. 6. Compound B increases plasma insulin levels in the SD rat hyperglycemic clamp model. A: Intravenous dosing with vehicle (■) or 10 mg/kg compound B (○) occurred immediately before intravenous infusion of glucose. Glucose levels measured from venous blood every 5 min are shown. Results are expressed as mean ± SEM. B: Blood glucose concentrations of ∼250 mg/dl were maintained throughout the experiment by varying the glucose infusion rates. C: Time course of plasma insulin concentrations in fasted animals treated with either vehicle (■) or compound B (○). Results are expressed as mean ± SEM. D: AUC20–60 min of the insulin secretion for vehicle (filled bar) versus compound B-treated (open bar) animals, *P < 0.05.CC BY-NC-ND · PubMed Central
FIG. 7. Compound B enhances insulin secretion in normal and diabetic human islets. A: Insulin concentrations from static cultures of normal human islets incubated in media containing high glucose (11.2 mmol/l) and either GLP-1 (100 nmol/l) or various concentrations of compound B (1–10 μmol/l). The treatments were performed for 90 min, and results are expressed as mean ± SEM, *P < 0.05. In perifusion experiments, insulin concentrations from reaction chambers containing 20 human islets from (B) normal or (C) diabetic individuals perifused with media containing either vehicle (■) or compound B (○) (3 or 10 μmol/l) in low glucose (3.3 mmol/l) for 40 min followed by high glucose (16.7 mmol/l) for an additional 35 min. AUC of the insulin excursion for vehicle versus compound B-treated (B) normal and (C) diabetic human islets, *P < 0.05.
FIG. 7. Compound B enhances insulin secretion in normal and diabetic human islets. A: Insulin concentrations from static cultures of normal human islets incubated in media containing high glucose (11.2 mmol/l) and either GLP-1 (100 nmol/l) or various concentrations of compound B (1–10 μmol/l). The treatments were performed for 90 min, and results are expressed as mean ± SEM, *P < 0.05. In perifusion experiments, insulin concentrations from reaction chambers containing 20 human islets from (B) normal or (C) diabetic individuals perifused with media containing either vehicle (■) or compound B (○) (3 or 10 μmol/l) in low glucose (3.3 mmol/l) for 40 min followed by high glucose (16.7 mmol/l) for an additional 35 min. AUC of the insulin excursion for vehicle versus compound B-treated (B) normal and (C) diabetic human islets, *P < 0.05.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 146

Metadata

Authors
Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., Gutierrez Sanfeliciano, S. M., Tebbe, M. J., & Coghlan, M. J.
Affiliations
  • Eli Lilly (United States) (US)
  • Discovery Chemistry Research and Technologies, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Corresponding author
Sloop, Kyle W.
Venue
Diabetes
Published
2010-09-07
Volume
59
Issue
12
Pages
3099-3107
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2142458050
Cited by
143
References
35
Citations by year
2026: 5 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 4 · 2021: 14 · 2020: 12 · 2019: 8 · 2018: 3 · 2017: 7 · 2016: 10 · 2015: 10 · 2014: 17 · 2013: 19 · 2012: 12
FWCI
10.17
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Keywords
GLP-1 receptor agonists, small molecule agonists, insulin secretion, type 2 diabetes, pyrimidine derivatives, cAMP signaling, glucose-dependent insulin secretion, human pancreatic islets, oral GLP-1 receptor agonists, drug discovery
MeSH terms
Glucagon-Like Peptide-1 Receptor, Insulin Secretion, Cyclic AMP, Animals, Gastric Inhibitory Polypeptide, Glucagon, Glucose Tolerance Test, Humans, Insulin, Islets of Langerhans, Luciferases, Male, Parathyroid Hormone, Vasoactive Intestinal Peptide, Rats, Sprague-Dawley, Genes, Reporter, Receptors, Glucagon, Rats, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets. https://app.cochat.ai/papers/10.2337/db10-0689
The paper
Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., Gutierrez Sanfeliciano, S. M., Tebbe, M. J., & Coghlan, M. J. (2010). Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets. Diabetes. https://doi.org/10.2337/db10-0689

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.